Dundee spinout Exscientia has filed for an offering that would provide exits for SoftBank Vision Fund 2, Novo, BMS, Celgene, Evotec and Pivotal BioVenture Partners.

Exscientia, a UK-based drug discovery technology developer backed by several corporate investors, filed for an initial public offering in the US on Friday, using a customary $100m placeholder amount.

The company has also secured a commitment from Bill and Melinda Gates Foundation to raise $35m in a concurrent private placement.

Founded in 2012, Exscientia has created an artificial intelligence-based software platform for end-to-end target identification, drug design and patient selection used in its drug development.

The company has three assets…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn